Aqara Previews New Devices for 2023
5.1.2023 17:00:00 EET | Business Wire | Press release
Aqara, a leading provider of smart home products, is set to expand its product portfolio in 2023 with the addition of innovative sensors, smart door locks, video doorbells and LED strips. Committed to providing seamless connected home experiences to millions of global users, Aqara continues to enrich its offerings with latest smart home technologies and new device types.
Video Doorbell G4 is complementary to Aqara’s indoor home cameras, and together these cameras help users to keep an eye on their homes, families and visitors anytime, anywhere. This doorbell allows highly flexible installation as it can be battery-powered or wired for continuous power. It not only supports HomeKit Secure Video and local streaming to Amazon and Google smart displays, but it will also work with Matter after the Matter specification for cameras is ready. The G4 features local, AI-enabled facial recognition, which can trigger different automations depending on the person, and the device also includes both the 7-day free cloud storage and the optional local storage via a microSD card.
Presence Sensor FP2 is a revolutionary addition to the Company’s wide-ranged sensor lineup. Based on the millimeter wave (mmWave) radar technology, the FP2 detects human presence even when the person is sitting still. It enables zone positioning, which allows users to define different zones within a room such as the bed, the dresser, or the sofa area, and the presence in each of these individual zone can trigger different automations for a more customized experience. Other features include multi-person detection, fall-detection and a built-in light sensor.
Smart Lock U100 is the first deadbolt lock from Aqara, offering a secure and convenient home access solution that can be seamlessly integrated into modern smart homes. The U100 lock is one of the few smart locks in the market that is compatible with HomeKit and supports the home key feature in Apple Wallet. Other access authentication options include fingerprints, passwords, Aqara Home app, NFC cards, and mechanical keys. Based on the Zigbee protocol, the U100 supports Matter via a compatible Aqara hub.
LED Strip T1 is a multipurpose RGB CCT lightstrip that is intended to enrich smart lighting experiences for Aqara users. It produces up to 16 million vibrant colors and tunable white light, and is addressable with gradient effects. HomeKit, Alexa and Google Home are supported, and Matter support via a compatible Aqara hub is expected to be added after its launch. The LED strip is Zigbee-based which means lower power consumption as well as less congested home Wi-Fi network, and it also serves as a repeater that enhances the Zigbee network.
These devices from Aqara will become available for purchase in the following months. For more information of these products, please check a demonstrative video here.
Committed to enabling seamless user experiences, Aqara has been working to integrate Matter into its existing and new devices. In 2023 new OTA updates will be pushed to Aqara hubs - beginning from the M2 - so that they can serve as Matter bridges and connect Aqara Zigbee devices to Matter. Moreover, the Company also confirmed a new lineup of Thread-based devices with native Matter support this year, including the Door and Window Sensor P2 and the Motion and Light Sensor P2 which are expected to hit the market in the coming months. As part of the ongoing partnerships with Aqara, both Google and Samsung are featuring these new sensors on respective booths at CES 2023, along with other Aqara devices including the Hub M2 as a Matter bridge.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005437/en/
Contact information
For Media Inquiry:
media@aqara.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom